Please login to the form below
antibiotic research
This page shows the latest antibiotic research news and features for those working in and with pharma, biotech and healthcare.
New research shows drug candidate may effectively treat antibiotic-resistant bacteria
Research published in The American Chemical Society Central Science journal has shown that Fabimycin may be effective against more than 200 antibiotic-resistant bacteria. ... A new drug candidate may be effective against more than 200
Latest news
-
Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide
Shionogi has teamed up with the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI) improve global access to antibiotics. ... Shionogi is proud to work on such an innovative licence agreement
-
The IMC unites health industry professionals to combat antibiotic resistant infections
The IMC partners are Antibiotic Research UK, the Association of British HealthTech Industries (ABHI), the Association of the British Pharmaceutical Industry (ABPI), BD, bioMérieux, the British In Vitro Diagnostics Association (BIVDA),
-
Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m
GSK still has some antibiotic assets, including its investigational drug gepotidacin which is being evaluated in phase 3 for the treatment of uncomplicated urinary tract infection (UT) and urogenital gonorrhoea. ... The pharma industry has refocused on
-
New Oxford research institute established to tackle antimicrobial resistance
It will build on Oxford’s expertise and legacy in the field of AMR and antibiotic research and drug discovery – scientists at the university made progress in making concentrated penicillin after ... The institute will also aim to spread awareness of
-
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
This pilot is intended to encourage drug developers to resume and increase research and development into new antibiotic medications, given that this area is lacking in innovation due to the economic ... Low use leads to limited revenues, which in turn
More from news
Approximately 2 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
How COVID-19 is accelerating the threat of antimicrobial resistance
This included the Global Antibiotic Research and Development Partnership (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). ... Other organisations across Europe also called on HCPs not to neglect antibiotic stewardship.
-
Combining therapies and combining research
Thankfully research is very much alive among the more agile, super-specialist research organisations. ... Combination therapy. Antibiotic Combination Therapy was developed in 1952 for the treatment of tuberculosis.
-
Another lost decade for research?
In contrast to the antibiotic field, our research, found in our separate report, Microbial infection: Point-of-care diagnostics, into patent filings relating to POC diagnostics over the past five years ... In terms of research focus, the majority of
-
Curbing the rise of drug resistance
The KPMG report urges governments and global life sciences businesses to invest more in antibiotic research and development, yet, the recent acquisition of Cubist Pharmaceuticals by Merck &Co. ... The authors’ full report: The global economic impact of
-
The impending threat of antibiotic resistance
Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do? ... Named Antibiotic Research UK (ANTRUK) the charity is the world's first dedicated to developing new antibiotics against antibiotic resistant infections.
More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Cubist picks Robert Perez as its new CEO
With Bonney as CEO Cubist has emerged as one of the leading players in antibiotic research, a field that has been neglected by larger pharma companies but is now a growing ... He said: “I am confident that we will drive excellence in the research,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Antibiotic resistance: The silent pandemic
Available at: https://www.sgu.edu/blog/medical/what-is-antibiotic-resistance/. Accessed November 2019. UK Research and Innovation. An introduction to antimicrobial resistance. ... Available at:
-
Adelphi Research UK Welcomes Six New Starters
During her time at Leeds she spent a year in a research laboratory. ... She has carried out exchange programmes in China and Hong Kong and has also completed two research internships in novel antibiotic discovery.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
